Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-masked study of intravitreal VEGF Trap-Eye versus ranibizumab in neovascular age-related macular degeneration
2007-000583-25Phase 3Completed
- Sponsor
- Bayer
- Start
- Dec 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exudative macular degeneration comparing VEGF Trap-Eye with Lucentis (2 arms). Primary endpoint: Primary efficacy endpoint. Started Dec 2007; status: completed.
02
Drugs
afliberceptranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2007-000583-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000583-25.